D. Boral Capital Maintains Buy on Cormedix, Maintains $14 Price Target

Benzinga · 12/18/2025 19:49
D. Boral Capital analyst Jason Kolbert maintains Cormedix (NASDAQ:CRMD) with a Buy and maintains $14 price target.